Occasional preclinical studies have investigated VEN in B- and T-ALL cell lines as well as primary samples, demonstrating encouraging results also in the high-risk subgroups of KMT2A and BCR::ABL1-rearranged B-ALL [12–19]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.